EVMN
What one share of Evommune holds
Pharmaceutical Preparations
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”).
Evommune’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.44 |
|---|---|
| Profit | −$4.15 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.27 |
| Cash and investments | $1.65 |
| Book value | $7.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | $4.64 | −$45.29 | $0.06 | −$38.64 | — | −$92.97 |
| 2025 | $2.12 | −$11.22 | $0.04 | −$12.49 | — | $6.52 |